Hepatic Disease in Patients With HIV
Summary
- Patients who cannot receive tenofovir disoproxil fumarate or tenofovir alafenamide because of current or high risk of renal dysfunction should be treated with a fully suppressive antiretroviral regimen that does not include either drug, and renally dosed entecavir should be added to the regimen (Management Guidelines)[DHHS OI]
- For patients with HIV and HBV coinfection and renal dysfunction but with creatinine clearance of 30 mL/min to 59 mL/min, an ART regimen containing tenofovir alafenamide and emtricitabine is preferred
- For patients with HIV and HBV coinfection and creatinine clearance < 30 mL/min, adding renally dosed entecavir to a suppressive non-tenofovir–containing ART regimen is preferred
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content